Agenda
Download Brochure
Flip through our 2024 conference brochure and discover what’s new this year.
- Jump to:
- At a Glance
- Day 1
- Day 2
- Print-friendly Format
Day 1 - Wednesday, May 29, 2024
7:30 |
Networking Breakfast and Registration |
8:30 |
Co-Chairs’ Opening Remarks: Pharma & Biotech Patent Litigation Year in Review |
9:15 |
C5's UPC InstituteRefining Life Sciences IP Litigation Strategies After the UPC’s Inaugural Year |
10:15 |
C5's UPC InstituteAdapting Approaches for Defending and Enforcing Patent Rights in Non-UPC Jurisdictions |
11:15 |
Morning Coffee Break |
11:45 |
C5's UPC InstituteThe UPC One Year Later: Judicial Insights on Year One |
12:45 |
Networking Lunch |
1:45 |
Navigating the New Landscape: Assessing the Impact of EU Pharmaceutical Legislation Reforms on Pharma and Biotech Litigation |
2:45 |
Deciphering Plausibility: Post-Publication Evidence in Inventive Step and the EPO’s G2/21 Decision |
3:45 |
Afternoon Break |
4:00 |
C5's SPC Think TankAdvancing SPC Strategies in the NEW EU SPC Landscape |
4:45 |
C5's SPC Think TankEvolving Dynamics of the SPC Manufacturing Waiver: Use, Impact, and Litigation Trends |
5:30 |
Conference Adjourns for Cocktail Reception |
Day 2 - Thursday, May 30, 2024
Day 1 - Wednesday, May 29, 2024
7:30 |
Networking Breakfast and Registration |
8:30 |
Co-Chairs’ Opening Remarks: Pharma & Biotech Patent Litigation Year in ReviewBethan Hopewell Rachel Mumby Ruud van der Velden Over the past year, the landscape of pharmaceutical and biotech patent litigation in Europe has undergone notable transformation. The activation of the Unified Patent Court inaugurated a new chapter in European patent litigation. The landscape has also been shaped by key decisions from the European Board of Appeal and legislative reforms in the pharmaceutical sector, introducing fresh challenges and strategies for patent practitioners. In this conference opening assessment, our 2024 co-chairs will delve into these significant developments, offering a comprehensive analysis of the evolving trends and their implications for life science patent law in 2024. |
9:15 |
C5's UPC InstituteRefining Life Sciences IP Litigation Strategies After the UPC’s Inaugural YearChristoph de Coster Oliver Jan Jüngst
|
10:15 |
C5's UPC InstituteAdapting Approaches for Defending and Enforcing Patent Rights in Non-UPC JurisdictionsRachel Fetches Otto Licks Josep Montefuso
|
11:15 |
Morning Coffee Break |
11:45 |
C5's UPC InstituteThe UPC One Year Later: Judicial Insights on Year OneHonorable Rian Kalden Honorable András Kupecz Honorable Edgar Brinkman Moderator:Professor Willem Hoyng This judicial roundtable offers a unique opportunity to gain insights from the judiciary’s viewpoint on the UPC’s operations and its impacts over the past year. The judges will share their experiences, challenges, and triumphs in navigating this new legal landscape. Attendees will benefit from a firsthand account of how the UPC has influenced patent litigation in Europe, including changes in procedural dynamics, case management, and decision-making trends. This engaging conversation will not only provide a retrospective look at the UPC’s inaugural year, but also offer foresight into future developments and ongoing evolution in European patent law. |
12:45 |
Networking Lunch |
1:45 |
Navigating the New Landscape: Assessing the Impact of EU Pharmaceutical Legislation Reforms on Pharma and Biotech LitigationBrigitte Carion-Taravella Jonas Löfgren Sergio Napolitano This session focuses on the transformative impact of the latest EU pharmaceutical legislation reforms on the pharma and biotech industries. Panelists will detail the implications of these changes, following the European Commission’s comprehensive overhaul, marked by the adoption of a new Directive and Regulation. Topics will include:
|
2:45 |
Deciphering Plausibility: Post-Publication Evidence in Inventive Step and the EPO’s G2/21 DecisionOliver Kingsbury Thomas Wolter This session will outline the nuances of the EPO Enlarged Board of Appeal’s G 2/21 decision, focusing on its implications for plausibility and inventive step in patent law. Discussion points include:
|
3:45 |
Afternoon Break |
4:00 |
C5's SPC Think TankAdvancing SPC Strategies in the NEW EU SPC LandscapeCordula Schumacher Jiri Slavik
|
4:45 |
C5's SPC Think TankEvolving Dynamics of the SPC Manufacturing Waiver: Use, Impact, and Litigation TrendsSabrina Duschner Frits Gerritzen This session will explore the latest developments in the application and impact of the SPC Manufacturing Waiver. Since its implementation, the waiver has shown a significant influence on the pharmaceutical industry, particularly in terms of manufacturing within the EU. Points of discussion will include:
|
5:30 |
Conference Adjourns for Cocktail Reception |
Day 2 - Thursday, May 30, 2024
8:00 |
Networking Breakfast |
8:30 |
Co-Chairs’ Welcome Back and Recap of Day 1 |
9:00 |
Strategic IP Management in Pharma & Biotech Litigation: Insights from Chief IP CounselFrank Landolt Julia Pike Shohta Ueno Moderator:Daan de Lange This opening session brings together leading Chief IP Counsel from both innovative and generic companies to share their insights and strategies for navigating the complexities of pharmaceutical and biotech IP in the European context. Points of discussion will cover: Innovator Perspectives:
Generic Perspectives:
Considerations for Both Sides:
|
10:00 |
Emerging Trends and Litigation Strategies for the Global Biologic and Biosimilar LandscapeNikolai Seltoft This session focuses on the dynamic global landscape of biosimilars and biologics, highlighting the latest trends, challenges, and strategies in patent litigation. Topics of discussion include:
|
10:45 |
Morning Coffee Break |
11:00 |
The Vaccine Patent Wars: Analysing the COVID-19 Litigation and the Implications for Life Sciences IPThierry Calame This session will detail the complex and pivotal patent litigations surrounding COVID-19 vaccines, offering life sciences IP lawyers in Europe critical insights into this rapidly evolving landscape. Session leaders will dissect the intersection of patent law, public health policy, and global access, highlighting strategic considerations and broader implications for the life sciences IP community. Topics of discussion will include:
|
11:45 |
EU Competition Law in the Life Sciences: New Developments, Enforcement Trends, and Economic ImpactsKarin Pramberger Gabriele Venskaityte As competition law continues to evolve, it is vital for life sciences IP practitioners in the pharmaceutical and biotech industries to stay informed about enforcement trends, litigation outcomes, and settlements, as well as the broader economic considerations that shape these laws. Points of discussion will include:
|
12:30 |
Networking Luncheon |
1:30 |
Advancements in Antibody Patent Litigation: Integrating 2023’s Key Rulings into 2024 StrategiesRoss Cummings This session addresses the continually evolving landscape of antibody patenting in Europe and the U.S., incorporating crucial case law developments from 2023 into effective prosecution strategies for 2024. Session leaders will dissect recent influential decisions and explore their implications for drafting and litigating antibody patents in different jurisdictions. Topics of discussion will include:
|
2:15 |
Priority Claims in Focus: Adapting to EPO’s New Stance in G 1/22 and G 2/22Willemijn Gommans Markus Grammel Gregor König This session will help you make sense of the recent landmark decisions by the EPO’s Enlarged Board of Appeal in G 1/22 and G 2/22, which have softened the approach to assessing entitlement to priority in patent applications. Topics of discussion include:
|
3:00 |
Afternoon Break |
3:15 |
Global Shifts in Life Sciences IP: Patent Linkage in China and Developments in the U.S.Robert Cerwinski This session will examine the evolving landscape of patent linkage litigation in China and recent developments in the U.S., providing critical insights for European companies. Points of discussion will include: China
United States
|
4:15 |
AI in Drug Discovery: Navigating Patent Challenges Amidst New Regulatory LandscapesMartin Herzog Jochen Spuck The landscape for patenting AI technologies in drug discovery is being shaped by new regulations and case law, impacting how companies approach IP protection and litigation. This session will detail the evolving challenges and opportunities in patenting AI-assisted drug discovery innovations, considering recent legal and regulatory developments in Europe and the U.S. Points of discussion will include:
|
5:15 |
Conference Concludes |